How to buy Anavex Life Sciences stock (AVXL)

Anavex Life Sciences is a biotechnology business based in the US. Anavex Life Sciences shares (AVXL) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $8.47 – an increase of 0.12% over the previous week. Anavex Life Sciences employs 40 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Anavex Life Sciences stock

Buy Anavex Life Sciences stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Anavex Life Sciences stock price (NASDAQ: AVXL)

Use our graph to track the performance of AVXL stocks over time.

Anavex Life Sciences shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$8.47
52-week range	$3.25 - $10.45
50-day moving average more info button	$7.41
200-day moving average more info button	$5.56
Wall St. target price	$35.47
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.51

Is it a good time to buy Anavex Life Sciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Anavex Life Sciences price performance over time

Historical closes compared with the close of $8.69 from 2024-12-18

1 week (2024-12-13)	2.72%
1 month (2024-11-20)	2.54%
3 months (2024-09-20)	54.08%
6 months (2024-06-20)	118.89%

1 year (2023-12-20)	-1.81%
2 years (2022-12-20)	-0.23%
3 years (2021-12-20)	18.11
5 years (2019-12-20)	254.69%

Anavex Life Sciences financials

Gross profit TTM	$0
Return on assets TTM	-20.43%
Return on equity TTM	-30.03%
Profit margin	0%
Book value	$1.53
Market Capitalization more info button	$736.9 million

TTM: trailing 12 months

Anavex Life Sciences share dividends

We're not expecting Anavex Life Sciences to pay a dividend over the next 12 months.

Have Anavex Life Sciences's shares ever split?

Anavex Life Sciences's shares were split on a 1:4 basis on 6 October 2015 . So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Anavex Life Sciences shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Anavex Life Sciences shares which in turn could have impacted Anavex Life Sciences's share price.

Anavex Life Sciences share price volatility

Over the last 12 months, Anavex Life Sciences's shares have ranged in value from as little as $3.25 up to $10.45. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Anavex Life Sciences's is 0.604. This would suggest that Anavex Life Sciences's shares are less volatile than average (for this exchange).

Anavex Life Sciences overview

Anavex Life Sciences Corp. , a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York. .

Frequently asked questions

null
What percentage of Anavex Life Sciences is owned by insiders or institutions?
Currently 3.048% of Anavex Life Sciences shares are held by insiders and 32.035% by institutions. How many people work for Anavex Life Sciences?
Latest data suggests 40 work at Anavex Life Sciences. When does the fiscal year end for Anavex Life Sciences?
Anavex Life Sciences's fiscal year ends in September. Where is Anavex Life Sciences based?
Anavex Life Sciences's address is: 630 5th Avenue, New York, NY, United States, 10111 What is Anavex Life Sciences's ISIN number?
Anavex Life Sciences's international securities identification number is: US0327973006 What is Anavex Life Sciences's CUSIP number?
Anavex Life Sciences's Committee on Uniform Securities Identification Procedures number is: 032797102